Page last updated: 2024-10-16

carbon monoxide and Dyspnea

carbon monoxide has been researched along with Dyspnea in 41 studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Dyspnea: Difficult or labored breathing.

Research Excerpts

ExcerptRelevanceReference
" The following parameters were also evaluated: pulmonary function tests including diffusion capacity for carbon monoxide (Dlco), the modified Medical Research Council dyspnea score, COPD assessment test (CAT), and 6-min walk test (6MWT)."3.85Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. ( Alcaide, AB; Bastarrika, G; Berto, J; Campo, A; Celli, BR; de-Torres, JP; Fernandez-Montero, A; Ocon, MD; Sanchez-Salcedo, P; Zulueta, JJ, 2017)
" Women with breast cancer had lower lung diffusing capacity for carbon monoxide (DLCO), respiratory and limb muscle strength, and ventilatory thresholds during exercise compared with controls (all P < 0."3.83Respiratory Factors Contributing to Exercise Intolerance in Breast Cancer Survivors: A Case-Control Study. ( Dudgeon, DJ; Elbehairy, AF; Langer, D; Neder, JA; O'Donnell, DE; Webb, KA, 2016)
" They had an unusual pattern of cardiopulmonary abnormalities with mild to moderate airway obstruction, severe hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide (p < 0."3.73Severe pulmonary hypertension and chronic obstructive pulmonary disease. ( Bugnet, AS; Chaouat, A; Ducoloné, A; Ehrhart, M; Enache, I; Kadaoui, N; Kessler, R; Schott, R; Weitzenblum, E, 2005)
" Spirometry, plethysmography, carbon monoxide diffusing capacity, 6-minute walking distance, and dyspnea score were assessed preoperatively and at predetermined times after operation."3.73Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation. ( Bloch, KE; Boehler, A; Imfeld, S; Korom, S; Lardinois, D; Russi, EW; Speich, R; Tutic, M; Weder, W, 2006)
"Respiratory dysfunction in Parkinson's disease (PD) is common and associated with increased hospital admission and mortality rates."3.01A systematic review and meta-analysis of respiratory dysfunction in Parkinson's disease. ( Blake, C; Lennon, O; McMahon, L, 2023)
"No treatment-emergent serious adverse events were reported."2.84Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. ( DiFede, D; Fishman, J; Glassberg, MK; Hare, JM; Khan, A; Lancaster, LH; LaRussa, VF; Mageto, YN; Mendizabal, A; Minkiewicz, J; Pujol, MV; Rosen, GD; Rubio, GA; Shafazand, S; Simonet, ES; Toonkel, RL, 2017)
"Up to 60% of the mice showed dyspnea, airway obstruction and hypoxemia and died between days 7 and 12 post-infection."1.36VEGF promotes malaria-associated acute lung injury in mice. ( Ataíde, R; Campos, MG; Carapau, D; Costa-Silva, A; Dias, S; Epiphanio, S; Félix, N; Marinho, CR; Monteiro, CA; Mota, MM; Pamplona, A; Pena, AC, 2010)
"The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings."1.34Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. ( Aduen, JF; Alvarez, F; Biewend, M; Jolles, HI; Keller, CA; Mobin, SI; Venegas, C; Zisman, DA, 2007)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-199010 (24.39)18.7374
1990's2 (4.88)18.2507
2000's9 (21.95)29.6817
2010's13 (31.71)24.3611
2020's7 (17.07)2.80

Authors

AuthorsStudies
Yeo, J1
Kim, JY1
Kim, MH1
Park, JW1
Park, JK1
Lee, EB1
MacIntyre, N1
Balasubramanian, A1
Kaminsky, D1
Matheson, AM1
McIntosh, MJ1
Kooner, HK1
Lee, J1
Desaigoudar, V1
Bier, E1
Driehuys, B1
Svenningsen, S1
Santyr, GE1
Kirby, M1
Albert, MS1
Shepelytskyi, Y1
Grynko, V1
Ouriadov, A1
Abdelrazek, M1
Dhaliwal, I1
Nicholson, JM1
Parraga, G1
Alves, MM1
Dressel, H1
Radtke, T1
Gülhan, PY1
Arbak, PM1
Annakkaya, AN1
Balbay, EG1
Balbay, ÖA1
McMahon, L1
Blake, C1
Lennon, O1
Ahn, J1
Yeghiaian-Alvandi, R1
Hegi-Johnson, F1
Browne, LH1
Graham, PH1
Chin, Y1
Gee, H1
Vinod, S1
Ludbrook, J1
Last, A1
Dwyer, P1
Ong, A1
Aherne, N1
Azzi, M1
Hau, E1
Natalini, JG1
Swigris, JJ1
Morisset, J1
Elicker, BM1
Jones, KD1
Fischer, A1
Collard, HR1
Lee, JS1
Garske, LA1
Kunarajah, K1
Zimmerman, PV1
Adams, L1
Stewart, IB1
Kaminsky, DA1
Jarzembowski, SC1
Nathan, SD1
Costabel, U1
Albera, C1
Behr, J1
Wuyts, WA1
Kirchgaessler, KU1
Stauffer, JL1
Morgenthien, E1
Chou, W1
Limb, SL1
Noble, PW1
Pezzuto, A1
Spoto, C1
Vincenzi, B1
Tonini, G1
Olukogbon, KL1
Thomas, P1
Colasanti, R1
Hope-Gill, B1
Williams, EM1
O'Donnell, DE1
Webb, KA1
Langer, D1
Elbehairy, AF1
Neder, JA1
Dudgeon, DJ1
Alcaide, AB1
Sanchez-Salcedo, P1
Bastarrika, G1
Campo, A1
Berto, J1
Ocon, MD1
Fernandez-Montero, A1
Celli, BR1
Zulueta, JJ1
de-Torres, JP1
Glassberg, MK1
Minkiewicz, J1
Toonkel, RL1
Simonet, ES1
Rubio, GA1
DiFede, D1
Shafazand, S1
Khan, A1
Pujol, MV1
LaRussa, VF1
Lancaster, LH1
Rosen, GD1
Fishman, J1
Mageto, YN1
Mendizabal, A1
Hare, JM1
Epiphanio, S1
Campos, MG1
Pamplona, A1
Carapau, D1
Pena, AC1
Ataíde, R1
Monteiro, CA1
Félix, N1
Costa-Silva, A1
Marinho, CR1
Dias, S1
Mota, MM1
Süyür, H1
Bayram, N1
Aydın, N1
Uyar, M1
Gündoğdu, N1
Elbek, O1
Gasior, N1
David, M1
Millet, V1
Reynaud-Gaubert, M1
Dubus, JC1
Lawson, K1
Maher, TM1
Hansell, DM1
Nicholson, AG1
KLEINFELD, M1
MESSITE, J1
SHAPIRO, J1
SWENCICKI, R1
KILBURN, KH1
Khanna, D1
Clements, PJ1
Furst, DE1
Chon, Y1
Elashoff, R1
Roth, MD1
Sterz, MG1
Chung, J1
FitzGerald, JD1
Seibold, JR1
Varga, J1
Theodore, A1
Wigley, FM1
Silver, RM1
Steen, VD1
Mayes, MD1
Connolly, MK1
Fessler, BJ1
Rothfield, NF1
Mubarak, K1
Molitor, J1
Tashkin, DP1
Chaouat, A1
Bugnet, AS1
Kadaoui, N1
Schott, R1
Enache, I1
Ducoloné, A1
Ehrhart, M1
Kessler, R1
Weitzenblum, E1
Snyder, EM1
Johnson, BD1
Beck, KC1
Tutic, M1
Lardinois, D1
Imfeld, S1
Korom, S1
Boehler, A1
Speich, R1
Bloch, KE1
Russi, EW1
Weder, W1
Aduen, JF1
Zisman, DA1
Mobin, SI1
Venegas, C1
Alvarez, F1
Biewend, M1
Jolles, HI1
Keller, CA1
Launay, D1
Mouthon, L1
Hachulla, E1
Pagnoux, C1
de Groote, P1
Remy-Jardin, M1
Matran, R1
Lambert, M1
Queyrel, V1
Morell-Dubois, S1
Guillevin, L1
Hatron, PY1
Schuller, A1
Cottin, V1
Hot, A1
Cordier, JF1
Courtney, R1
Cohen, M1
Hazelrigg, S1
Boley, T1
Henkle, J1
Lawyer, C1
Johnstone, D1
Naunheim, K1
Keller, C1
Keenan, R1
Landreneau, R1
Sciurba, F1
Feins, R1
Levy, P1
Magee, M1
Long, W1
Tate, RB1
Neuman, M1
Manfreda, J1
Becker, AB1
Anthonisen, NR1
Scano, G1
Filippelli, M1
Romagnoli, I1
Mancini, M1
Misuri, G1
Duranti, R1
Rosi, E1
Lough, J1
Baudouin, J1
Thevenot, C1
Dezile, G1
Lavandier, M1
Homasson, JP1
Roullier, A1
Rubin, G1
Baume, P1
Vandenberg, R1
Emirgil, C1
Sobol, BJ1
Heymann, B1
Shibutani, K1
Miller, GJ1
Hearn, CE1
Edwards, RH1
Bates, DV1
Bell, GM1
Burnham, CD1
Hazucha, M1
Mantha, J1
Pengelly, LD1
Silverman, F1
Renzetti, AD1
Kobayashi, T1
Bigler, A1
Mitchell, MN1
Petrilli, FL1
Agnese, G1
Kanitz, S1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Utility of Breath-holding Test for Assessment of Pulmonary Disease Severity in Patients With Systemic Sclerosis[NCT04484948]120 participants (Actual)Interventional2020-08-12Completed
Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI and CT For Rapid Evaluations and NExt-wave Healthcare Planning[NCT04584671]100 participants (Anticipated)Observational2021-01-01Active, not recruiting
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis[NCT00287729]Phase 3344 participants (Actual)Interventional2006-04-30Completed
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)[NCT01366209]Phase 3555 participants (Actual)Interventional2011-06-30Completed
A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis[NCT00287716]Phase 3435 participants (Actual)Interventional2006-07-14Completed
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130]60 participants (Anticipated)Observational [Patient Registry]2017-01-01Recruiting
A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis[NCT02013700]Phase 19 participants (Actual)Interventional2013-11-13Terminated (stopped due to Study completed)
An Open Clinical Study to Explore the Safety, Tolerance and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)[NCT05468502]Phase 118 participants (Anticipated)Interventional2022-10-10Recruiting
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129]Phase 2142 participants (Actual)Interventional2009-09-30Completed
Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität[NCT01423071]220 participants (Actual)Observational2011-08-31Completed
A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256]Phase 229 participants (Actual)Interventional2012-11-30Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities)
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269]Phase 217 participants (Actual)Interventional2013-03-31Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities)
Dysfunctional Breathing: Multidimensional Characterisation and Assessment Tool[NCT03043469]141 participants (Anticipated)Observational2020-08-08Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Percent Predicted Forced Vital Capacity(FVC)

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements. (NCT00287729)
Timeframe: Baseline to week 72

InterventionChange in Percent Predicted FVC (Mean)
Pirfenidone (2403 mg/d)-9
Placebo-10

Change in Dyspnea Score

The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness. (NCT00287729)
Timeframe: Baseline to Week 72

InterventionChange in Dyspnea Score (Mean)
Pirfenidone (2403 mg/d)11.9
Placebo13.9

Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs

The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements. (NCT00287729)
Timeframe: Baseline to Week 72

InterventionChange in Percent Predicted DLco (Mean)
Pirfenidone (2403 mg/d)-9.8
Placebo-9.2

Change in the Six-Minute Walk Test (6MWT) Distance

The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m). (NCT00287729)
Timeframe: Baseline to Week 72

InterventionChange in Distance Walked in Meters (Mean)
Pirfenidone (2403 mg/d)-45
Placebo-77

Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements. (NCT00287729)
Timeframe: Baseline to Week 72

InterventionChange,Worst Oxygen Saturation (Percent) (Mean)
Pirfenidone (2403 mg/d)-1.9
Placebo-1.3

Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity

Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (<10% but >=0% decline), moderate decline (<20% but >=10% decline), severe decline (>=20% decline), mild improvement (>0% but <10% improvement), or moderate improvement (>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity. (NCT00287729)
Timeframe: Baseline to week 72

,
InterventionPatients (Number)
Decline >=20% or death or lung transplantationDecline <20% but >= 10%Decline <10% but > 0%Improvement of >=0% but <10%Improvement of >=10%
Pirfenidone (2403 mg/d)201988413
Placebo232389335

Progression-free Survival

Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death. (NCT00287729)
Timeframe: Baseline to Week 72

,
InterventionNumber of Patients with Progression (Number)
Death or Disease ProgressionDecline in percent predicted FVC >=10%Decline in percent predicted DLco >=15%Death Before Disease Progression
Pirfenidone (2403 mg/d)54311013
Placebo6041910

Worsening of IPF

"Worsening of IPF was defined by the occurrence of any of the following events:~Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization." (NCT00287729)
Timeframe: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.

,
InterventionNumber of Patients Who Worsened (Number)
Woresening IPFAcute IPF exacerbationIPF-related deathLung transplantationRespiratory hospitalizationPatients Censored
Pirfenidone (2403 mg/d)2423217146
Placebo3216223141

Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52

(NCT01366209)
Timeframe: 52 weeks

,
Interventionpercentage of patients (Number)
Decline or >=10% or DeathNo Decline (Change >0%)
Active Arm16.522.7
Placebo Arm31.89.7

Absolute Change in Percent Predicted Forced Vital Capacity (FVC)

Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. (NCT00287716)
Timeframe: From baseline up to 72 weeks

InterventionChange in Percent Predicted FVC (Mean)
Pirfenidone 2403 mg/Day-8.0
Pirfenidone 1197 mg/Day-10.0
Placebo-12.4

Change in Dyspnea Score

The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5), with 0 = not at all breathless, 4= severely breathless and 5 = Maximally or unable to do because of breathlessness. (NCT00287716)
Timeframe: Baseline to Week 72

InterventionChange in Dyspnea Score (Mean)
Pirfenidone 2403 mg/Day12
Pirfenidone 1197 mg/Day14
Placebo15

Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs

(NCT00287716)
Timeframe: Baseline to Week 72

InterventionChange in Percent Predicted DLco (Mean)
Pirfenidone 2403 mg/Day-8
Pirfenidone 1197 mg/Day-9
Placebo-10

Change in Six-Minute Walk Test (6MWT)Distance

The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test as measured in meters (m). (NCT00287716)
Timeframe: Baseline to Week 72

InterventionChange in Distance Walked in Meters (Mean)
Pirfenidone 2403 mg/Day-60
Pirfenidone 1197 mg/Day-76
Placebo-77

Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test

The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements. (NCT00287716)
Timeframe: Baseline to Week 72

InterventionChange,Worst Oxygen Saturation (Percent) (Mean)
Pirfenidone 2403 mg/Day-2
Pirfenidone 1197 mg/Day-1
Placebo-2

Worsening of Idiopathic Pulmonary Fibrosis (IPF)

"Worsening of IPF was defined by the occurrence of any of the following events:~Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization." (NCT00287716)
Timeframe: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.

InterventionNumber of Patients Who Worsened (Number)
Pirfenidone 2403 mg/Day26
Pirfenidone 1197 mg/Day10
Placebo30

Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity (FVC)

Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (<10% but >=0% decline), moderate decline (<20% but >=10% decline), severe decline (>=20% decline), mild improvement (>0% but <10% improvement), or moderate improvement (>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experienced a Categorical Change in Percent Predicted Forced Vital Capacity. (NCT00287716)
Timeframe: baseline up to 72 weeks

,,
InterventionPatients (Number)
Severe decline of >=20%, death, or lung transplantModerate decline of <20% but >=10%Mild decline of <10% but >=0%Mild improvement of >0% but <10%Moderate improvement of >=10%
Pirfenidone 1197 mg/Day91451121
Pirfenidone 2403 mg/Day142197402
Placebo273390240

Progression-free Survival (PFS)

Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death. (NCT00287716)
Timeframe: Baseline to Week 72

,,
InterventionNumber of Patients with Progression (Number)
Death or Disease ProgressionDecline in Percent Predicted FVC >=10%Decline in Percent Predicted DLco >=15%Death Before Disease Progression
Pirfenidone 1197 mg/Day281657
Pirfenidone 2403 mg/Day452898
Placebo6239914

Fibrosis Score, as Measured by Thoracic High Resolution Computerized Tomography (HRCT)

Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24

,
Intervention% of lung exhibiting QLF (Mean)
BaselineMonth 24
Cyclophosphamide Arm8.918.48
Mycophenolate Arm8.257.99

Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24

,
InterventionFVC %-pred (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm66.5267.0367.8669.4269.8671.9472.5772.5570.15
Mycophenolate Arm66.5266.2268.0268.1168.4369.8470.5770.8769.65

Health-related Quality of Life as Measured by the Patient Responses to the Health Assessment Questionnaire Disability Index (HAQ-DI)

The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24

,
InterventionHAQ-DI Total Score (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm0.740.640.580.650.560.620.550.480.57
Mycophenolate Arm0.710.830.750.660.640.580.550.650.62

Single-breath Diffusing Capacity for Carbon Monoxide (DLCO), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24

,
InterventionDLCO %-pred (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm54.0551.9250.8751.5553.1253.6255.954.2652.90
Mycophenolate Arm53.9953.3854.8654.1355.3257.7756.6255.4755.31

Skin Involvement, as Measured by the Modified Rodnam Skin Thickness Scores (mRSS)

Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24

,
InterventionmRSS score (Mean)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm14.0412.8511.9510.619.479.809.878.507.87
Mycophenolate Arm15.3216.0314.3714.3312.4512.4311.9811.2211.40

Tolerability, as Assessed by the Time to Withdrawal From the Study Drug or Meeting Protocol-defined Criteria for Treatment Failure.

The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months

,
InterventionParticipants (Count of Participants)
BaselineMonth 3Month 6Month 9Month 12Month 15Month 18Month 21Month 24
Cyclophosphamide Arm736456514644423938
Mycophenolate Arm696658555252494949

Total Lung Capacity (TLC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value

The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24

,
InterventionTLC %-pred (Mean)
BaselineMonth 6Month 12Month 18Month 24
Cyclophosphamide Arm65.4967.3968.2569.6366.97
Mycophenolate Arm66.1667.8467.3168.5068.24

Toxicity, as Measured by Adverse Events, Serious Adverse Events, and Death

(NCT00883129)
Timeframe: Measured throughout the 2-year study

,
InterventionParticipants (Count of Participants)
Leukopenia (<2.5x10^3 WBC/microliter)Neutropenia (<1.0x10^3 neutrophils/microliter)Anemia (Hgb <10 g/dl)Thrombocytopenia (<100x10^3 platelets/microliter)Hematuria (>10 RBC/high power field)PneumoniaSAE-TotalSAE-related to treatmentDeaths
Cyclophosphamide Arm3071342422711
Mycophenolate Arm4380352735

Transitional Dyspnea Index Score

Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24

,
InterventionTransitional Dyspnea Index Score (Mean)
Month 6Month 12Month 18Month 24
Cyclophosphamide Arm0.311.231.782.09
Mycophenolate Arm0.741.170.911.86

Reviews

2 reviews available for carbon monoxide and Dyspnea

ArticleYear
A systematic review and meta-analysis of respiratory dysfunction in Parkinson's disease.
    European journal of neurology, 2023, Volume: 30, Issue:5

    Topics: Carbon Monoxide; Case-Control Studies; Cough; Disease Progression; Dyspnea; Humans; Lung Volume Meas

2023
[Adult respiratory sequelae of premature birth].
    Revue des maladies respiratoires, 2011, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Bronchial Hyperreactivity; Bronchopulmonary Dysplasia; Carbon Monoxide; Disease P

2011

Trials

4 trials available for carbon monoxide and Dyspnea

ArticleYear
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Respiratory medicine, 2019, Volume: 153

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud

2019
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Chest, 2017, Volume: 151, Issue:5

    Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz

2017
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Chest, 2017, Volume: 151, Issue:5

    Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz

2017
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Chest, 2017, Volume: 151, Issue:5

    Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz

2017
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
    Chest, 2017, Volume: 151, Issue:5

    Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz

2017
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Arthritis and rheumatism, 2005, Volume: 52, Issue:2

    Topics: Carbon Monoxide; Double-Blind Method; Dyspnea; Female; Health Status; Humans; Lung Diseases; Male; M

2005
An open-circuit method for determining lung diffusing capacity during exercise: comparison to rebreathe.
    Journal of applied physiology (Bethesda, Md. : 1985), 2005, Volume: 99, Issue:5

    Topics: Adult; Carbon Monoxide; Cardiac Output; Dyspnea; Exercise; Female; Humans; Male; Middle Aged; Pulmon

2005

Other Studies

35 other studies available for carbon monoxide and Dyspnea

ArticleYear
Utility of the breath-holding test in patients with systemic sclerosis.
    Rheumatology (Oxford, England), 2022, 10-06, Volume: 61, Issue:10

    Topics: Biomarkers; Carbon Monoxide; Dyspnea; Humans; Reproducibility of Results; Scleroderma, Systemic; Str

2022
Diffusing Capacity of the Lungs for Carbon Monoxide Test.
    JAMA, 2022, Feb-01, Volume: 327, Issue:5

    Topics: Breath Holding; Breath Tests; Carbon Monoxide; Dyspnea; Forced Expiratory Volume; Hemoglobin A; Huma

2022
Persistent
    Radiology, 2022, Volume: 305, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; COVID-19; Dyspnea; Female; Humans; Lung

2022
Test-retest reliability of lung diffusing capacity for nitric oxide during light to moderate intensity cycling exercise.
    Respiratory physiology & neurobiology, 2022, Volume: 304

    Topics: Adult; Aged; Carbon Monoxide; Dyspnea; Humans; Hyperplasia; Lung; Middle Aged; Nitric Oxide; Pulmona

2022
An assessment of post-COVID-19 infection pulmonary functions in healthcare professionals.
    American journal of infection control, 2022, Volume: 50, Issue:10

    Topics: Adult; Carbon Monoxide; COVID-19; Delivery of Health Care; Dyspnea; Female; Humans; Lung; Male; Midd

2022
SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
    International journal of radiation oncology, biology, physics, 2023, Dec-01, Volume: 117, Issue:5

    Topics: Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Dyspnea; Humans; Lung; Lung Neoplasms; Prospective

2023
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
    Respiratory medicine, 2017, Volume: 127

    Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Dyspnea; Female; Forced Expiratory Vol

2017
In patients with unilateral pleural effusion, restricted lung inflation is the principal predictor of increased dyspnoea.
    PloS one, 2018, Volume: 13, Issue:10

    Topics: Carbon Monoxide; Chromatography, Thin Layer; Diaphragm; Dyspnea; Female; Humans; Lung; Male; Pleura;

2018
Influence of Mouth Pressure on Measurement of Diffusing Capacity in the Clinical Pulmonary Function Laboratory.
    Respiratory care, 2019, Volume: 64, Issue:5

    Topics: Adult; Aged; Asthma; Breath Holding; Carbon Monoxide; Dyspnea; Female; Forced Expiratory Volume; Hum

2019
Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level.
    Journal of comparative effectiveness research, 2013, Volume: 2, Issue:3

    Topics: Benzazepines; Carbon Monoxide; Carboxyhemoglobin; Carcinoembryonic Antigen; Combined Modality Therap

2013
Breathing pattern and breathlessness in idiopathic pulmonary fibrosis: An observational study.
    Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:2

    Topics: Aged; Aged, 80 and over; Carbon Monoxide; Case-Control Studies; Dyspnea; Exhalation; Female; Humans;

2016
Respiratory Factors Contributing to Exercise Intolerance in Breast Cancer Survivors: A Case-Control Study.
    Journal of pain and symptom management, 2016, Volume: 52, Issue:1

    Topics: Breast Neoplasms; Cancer Survivors; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Test; E

2016
Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.
    Chest, 2017, Volume: 151, Issue:2

    Topics: Activities of Daily Living; Aged; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Dy

2017
VEGF promotes malaria-associated acute lung injury in mice.
    PLoS pathogens, 2010, May-20, Volume: 6, Issue:5

    Topics: Acute Lung Injury; Airway Obstruction; Animals; Anti-Inflammatory Agents; Carbon Monoxide; Disease M

2010
[Pulmonary manifestations of polyvinyl chloride exposure].
    Tuberkuloz ve toraks, 2011, Volume: 59, Issue:1

    Topics: Adult; Carbon Monoxide; Cough; Diffusion; Dust; Dyspnea; Female; Humans; Incidence; Lung Diseases; M

2011
Successful treatment of progressive diffuse PEComatosis.
    The European respiratory journal, 2012, Volume: 40, Issue:6

    Topics: Adult; Biopsy; Carbon Monoxide; Cell Proliferation; Dyspnea; Female; Genotype; Humans; Lung; Lung Di

2012
EFFECT OF TALE DUST INHALATION ON LUNG FUNCTION.
    Archives of environmental health, 1965, Volume: 10

    Topics: Bradycardia; Carbon Monoxide; Cardiomegaly; Cough; Dust; Dyspnea; Electrocardiography; Oximetry; Pne

1965
TACHYPNEA AND HYPERPNEA; SIGNS OF COMPENSATORY VENTILATION.
    Annals of internal medicine, 1965, Volume: 62

    Topics: Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Carbon Dioxide; Carbon Monoxide; Dyspnea; H

1965
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2005, Jul-15, Volume: 172, Issue:2

    Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum

2005
Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation.
    The Annals of thoracic surgery, 2006, Volume: 82, Issue:1

    Topics: Adult; Aged; Carbon Monoxide; Dyspnea; Exercise Test; Female; Follow-Up Studies; Forced Expiratory V

2006
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Dyspnea; Echocardiography; Female; Humans; Lung Dis

2007
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    The Journal of rheumatology, 2007, Volume: 34, Issue:5

    Topics: Adult; Carbon Monoxide; Comorbidity; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases

2007
Finger clubbing and altered carbon monoxide transfer capacity in cannabis smokers.
    The European respiratory journal, 2008, Volume: 31, Issue:2

    Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Dyspnea; Follow-Up Studies; Humans; Male; Marijuana Smok

2008
Investigating the claims of Konstantin Buteyko, M.D., Ph.D.: the relationship of breath holding time to end tidal CO2 and other proposed measures of dysfunctional breathing.
    Journal of alternative and complementary medicine (New York, N.Y.), 2008, Volume: 14, Issue:2

    Topics: Adult; Breath Tests; Breathing Exercises; Carbon Monoxide; Dyspnea; Female; Humans; Male; Reference

2008
Thoracoscopic laser bullectomy: a prospective study with three-month results.
    The Journal of thoracic and cardiovascular surgery, 1996, Volume: 112, Issue:2

    Topics: Acid-Base Imbalance; Adult; Aged; Blister; Carbon Dioxide; Carbon Monoxide; Dyspnea; Echocardiograph

1996
Respiratory symptoms in a susceptible population due to burning of agricultural residue.
    Chest, 1998, Volume: 113, Issue:2

    Topics: Adult; Agriculture; Air Pollutants; Air Pollution; Airway Obstruction; Asthma; Bronchial Hyperreacti

1998
Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus.
    Chest, 2000, Volume: 117, Issue:4

    Topics: Adult; Breath Tests; Carbon Dioxide; Carbon Monoxide; Diabetes Mellitus, Type 1; Dyspnea; Elasticity

2000
Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs.
    Archives of pathology & laboratory medicine, 1978, Volume: 102, Issue:7

    Topics: Animals; Carbon Monoxide; Cardiomegaly; Cyanosis; Dyspnea; Guinea Pigs; Heart Diseases; Male; Mitoch

1978
[Pulmonary fibrosis by hard metals. Functional and immunological study of 4 cases].
    Revue de l'Institut d'hygiene des mines, 1974, Volume: 29, Issue:3

    Topics: Adult; Aged; Carbon; Carbon Monoxide; Cobalt; DNA; Dyspnea; Humans; Immunoglobulin E; Immunologic De

1974
Azathioprin nd acute restrictive lung disese.
    Australian and New Zealand journal of medicine, 1972, Volume: 2, Issue:3

    Topics: Acute Disease; Adult; Azathioprine; Carbon Monoxide; Colitis, Ulcerative; Cough; Dyspnea; Humans; Lu

1972
Pulmonary function in alcoholics.
    The American journal of medicine, 1974, Volume: 57, Issue:1

    Topics: Adult; Alcoholism; Bronchitis; Carbon Monoxide; Disease Susceptibility; Dyspnea; Ethanol; Female; Hu

1974
Pulmonary function at rest and during exercise following bagassosis.
    British journal of industrial medicine, 1971, Volume: 28, Issue:2

    Topics: Blood Volume; Capillaries; Carbon Monoxide; Cromolyn Sodium; Dyspnea; Fungi; Humans; Hypercapnia; Lu

1971
Short-term effects of ozone on the lung.
    Journal of applied physiology, 1972, Volume: 32, Issue:2

    Topics: Adult; Airway Resistance; Analysis of Variance; Carbon Monoxide; Cough; Dyspnea; Humans; Lung; Lung

1972
Regional ventilation and perfusion in silicosis and in the alveolar-capillary block syndrome.
    The American journal of medicine, 1970, Volume: 49, Issue:1

    Topics: Adult; Aged; Arthritis, Rheumatoid; Body Surface Area; Bronchitis; Capillaries; Carbon Dioxide; Carb

1970
Epidemiologic studies of air pollution effects in Genoa, Italy.
    Archives of environmental health, 1966, Volume: 12, Issue:6

    Topics: Air Pollution; Benzopyrenes; Bronchitis; Carbon Monoxide; Cough; Dyspnea; Environmental Health; Fema

1966